Lantheus Holdings, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2022
February 24, 2022 at 07:00 am EST
Share
Lantheus Holdings, Inc. provided earnings guidance for the first quarter and full year of 2022. For the First quarter, the company expects revenue in range of $160 million to $170 million.
For the year, the company expects revenue in range of $685 million to $710 million.
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company. The Company is engaged in delivering science to enable clinicians to find, fight and follow disease to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Its Radiopharmaceutical Oncology diagnostics and therapeutic candidates help healthcare professionals (HCPs) find, fight, and follow cancer, with a focus in prostate cancer. Its Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Its Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma solutions platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, NEUROLITE, Xenon-133, CARDIOLITE, RELISTOR, Automated Bone Scan Index, and others. Its commercial products are used by cardiologists, internal medicine physicians, and others.
LANTHEUS HOLDINGS, INC. 
